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ABSTRACT
Background: While Polycystic Ovary Syndrome (PCOS) is a medical condition that impacts
women of childbearing age, prior research has shown that women of color are at a
disproportionately higher risk. The goal of this meta research project is to closely model a
systematic process to assess demographic characteristics of participants recruited and enrolled in
clinical trials and RCTs in PCOS-related research studies. Methods: An exhaustive electronic
database search was performed through Ovid MEDLINE, PubMed, Scopus, Ovid Embase, and
Web of Science to identify studies that focused on PCOS-related infertility. Out of the 2,883
records identified in the initial search strategy, eight studies met the final search criteria. Results:
Among the eight studies identified in the final search criteria, three studies (37.5%) failed to
report the race or ethnicity of the enrolled participants. Meanwhile, while five studies (62.5%)
did provide information about the patients’ racial and demographic characteristics, only two
studies (25%) included population samples that were vastly women of color. The remaining three
studies (37.5%) involved an overwhelming majority of white women in the recruitment sample.
None of the eight studies reported or stratified findings across race or ethnicity metrics.
Discussion: None of the authors outlined the recruitment methodology nor sampling techniques
when selecting participants for these clinical trials. For the five studies who reported on patient
demographics, the only information provided was a baseline characteristics table, which outlined
characteristics such as average age, BMI, and race/ethnicity of the study subjects. The findings
from this study highlight the critical need for future clinical trials to account for racial and ethnic
diversity in the sampling methodology and inclusion of research participants.
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BACKGROUND
Polycystic Ovary Syndrome (PCOS) is a medical condition that impacts 10% of women of
childbearing age, characterized by an imbalance in reproductive hormones which can cause
various metabolic abnormalities, infertility, and other gestational/physical complications.1 There
are five major hormones that play a role in PCOS related complications: 1) Androgens, also
known as male sex hormones. While androgens are present in the bodies of both males and
females, women with PCOS tend to produce an abnormal amount of androgens, which can cause
menstrual cycle irregularities, hinder ovulation, increase production of facial/body hair/acne, and
lead to the development of ovarian cysts.2 2) Insulin, which plays a major role in managing
blood glucose levels in the body. Women with PCOS are more likely to be insulin resistant - their
bodies can produce insulin, but they can’t use it effectively or efficiently which increases their
risk for Type II Diabetes.3 3) Luteinizing hormone (LH) and 4) Follicle-stimulating hormones
(FSH) - both of which are secreted by the pituitary gland. LH helps to control the production of
estrogen and progesterone in the ovary, while FSH controls the development and release of the
eggs in a woman’s ovary.4 Women with PCOS tend to have lower levels of both FSH and LH,
which contributes to difficulties with ovulation and higher rates of infertility. 5) Progesterone,
which is a hormone released by the ovaries and influences the menstrual cycle and pregnancy.
Women with PCOS tend to suffer from an imbalance in progesterone, which can cause menstrual
cycle irregularities and an increased risk for infertility.5

While PCOS can affect women of all racial and ethnic backgrounds, prior research studies have
shown that minority women of color may present an elevated risk of PCOS-related infertility and
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other health disparities compared with non-minority white women.6 According to researchers
Braveman et al., health disparities are health differences that adversely affect socially
disadvantaged groups and are systemic, plausibly avoidable health differences on the basis of
race/ethnicity, colorism, religion, nationality, socioeconomic status, education, occupation,
gender/gender identity, sexual orientation, age, geography, disability, illness, or other
characteristics associated with discrimination or marginalization.7 Over the years, social science
researchers have highlighted the pervasive role that historical systems of oppression, structural
inequities, and racism have played in generating social disadvantage and health disparities
among minority people of color. Researchers Link and Phelan have asserted that both racism and
socioeconomic status are fundamental causes of social inequities and mortality because they
influence multiple disease outcomes, are associated with multiple risk factors, are reproduced
over time, and involve access to resources that can be used to minimize or avoid such risks.8
Additionally, researchers Fullilove et al. have explained how the spillover effects of racism have
generated and contributed to racial residential segregation, whereby policymakers, housing
authorities, and community planners have used tactics such as redlining, serial forced
displacement, urban renewal, and gentrification to push minority people of color out of
historically white neighborhoods.9 Consequently, these communities of color are often forced to
relocate into concentrated areas that are frequently under-resourced, low-income, and suffer from
high rates of food insecurity, limited job opportunities, and poorer access to healthcare. The
inverse hazards law posits that these types of negative consequences accumulate inversely with
power and resources, which typically affects minority communities of color and places them at
higher risk for disease-related illness and mortality.10 The compounding effects of structural and
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systemic injustices have generated elevated risks for these minority communities of color,
placing them at higher risks for various chronic and long-term illnesses. Despite progressive
changes in disease management and treatment, it is clear that race-related disparities have
continued to persist over time, with detrimental costs to individual-level health.

The National Institutes of Health estimates that 40 to 85% of women with PCOS are either
overweight or obese, which is a risk factor to PCOS.11 Furthermore, The Centers for Disease
Control and Prevention (CDC) have reported that non-white people of color have the highest
rates of obesity in the U.S. Specifically, their most recent report released in 2021 revealed that
Non-Hispanic Black adults had the highest age-adjusted prevalence of obesity (49.6%), followed
by Hispanic adults (44.8%).12 With knowledge that Black and Hispanic Americans have higher
morbidity and mortality rates due to cardiovascular diseases and diabetes mellitus in the general
population than white Americans, a 2017 study by researchers Engmann et al. studied the effects
of racial and ethnic differences in PCOS metabolic phenotypes as it relates to insulin resistance,
metabolic syndrome, and hyperandrogenemia. The study found that Hispanic women with PCOS
had a significantly higher prevalence of hirsutism (93.8 vs. 86.8%), abnormal free androgen
index (75.8 vs. 56.5%), abnormal homeostasis model assessment (52.3 vs. 38.4%),
hyperglycemia (14.8 vs. 6.5%), and lower sex hormone binding globulin compared to
non-Hispanic Whites. Furthermore, Non-Hispanic Black women had a significantly lower
prevalence of metabolic syndrome (24.5 vs. 42.2%) compared with Hispanic women, and lower
serum triglyceride levels compared to both Hispanics and non-Hispanic Whites (85.7 ± 37.3 vs.
130.2 ± 57.0 vs. 120.1 ± 60.5mg/dL, p<0.01), and a lower prevalence of hypertriglyceridemia
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(5.1 vs. 28.3 vs. 30.5%, p<0.01) compared to the other two groups.13 These findings highlight the
critical need to understand the racial and ethnic differences in metabolic syndrome for women
with PCOS in identifying effective prevention and treatment strategies.14

Over the years, various clinical trials on pharmacotherapy drug treatments have been assessed in
treating infertility-related PCOS in women. Currently, the four most common and effective drug
treatments for ovulation induction used by physicians include: 1) Clomiphene: An estrogen
modulator used to induce egg production among infertile women; 2) Letrozole: A non-steroidal
aromatase inhibitor commonly used to treat breast cancer but also works to stimulate ovaries; 3)
Metformin: An oral medication commonly used to treat type II diabetes but also serves as an
effective ovulation induction agent for non-obese women with PCOS; and 4) Gonadotropins:
Peptide hormonal injection shots that can regulate the reproductive system and stimulate
ovulation.15,16,17,18,19 However, with knowledge that PCOS tends to disproportionately affect
minority women of color, it is important to uncover whether previous clinical trials and
randomized controlled trials (RCTs) have considered patient demographic characteristics in the
study design, methodology, and enrollment of patients into these clinical trials.

A 2015 article by researchers Oh et al. assessed diversity representation in clinical and
biomedical research. Their findings illustrated that while racial and ethnic minorities comprise
nearly 40% of the U.S. population, they remain severely under-represented in many clinical
trials.20 Citing one example, the study found that less than 5% of NIH-funded respiratory
research reported inclusion of racial and ethnic minorities.21 By failing to include racial and
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ethnic representation in these clinical trials, there continues to be a significant gap in
understanding and research regarding the factors that contribute to inequitable and
disproportionate burdens of health among minority populations.

Despite ample studies and research of PCOS in academic discourse, there have been no
identified studies to date that have critically assessed racial representation in the methodology
and recruitment of these PCOS-related clinical trials. The goal of this meta research project is to
fill this gap in research by closely modeling a systematic process to assess demographic
characteristics of the study subjects recruited and enrolled in clinical trials and RCTs researching
the efficacy of pharmacotherapy fertility treatments for women with Polycystic Ovary Syndrome
(PCOS). The primary objective of this thesis is to conduct a comprehensive meta research
assessment of prior clinical trial studies and randomized controlled trials in order to assess
whether the studies reflect representative samples of the U.S. population - specifically with
regard to race and ethnicity-related factors. Understanding the patient demographics of the
various studies will help understand whether the clinical trials and RCTs that evaluate the
treatments for PCOS are representative of the true populations who need treatment. As a
secondary objective, this thesis will also assess the ovulatory, pregnancy, and fertility-related
outcomes associated with the various pharmacotherapy drug treatments for PCOS in order to
deduce any striking patterns stratified across race or ethnicity, such as whether certain drug
treatments tended to be disproportionately prescribed to or utilized by certain racial or ethnic
groups. I hypothesize that study recruitment across the reviewed studies will illustrate an overall
non-representative sample of the U.S. population affected by PCOS. The findings generated in
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this paper are critical in ensuring that fertility treatment and population health outcomes are
optimized across all patient demographics. The results from this meta research project will have
the potential to inform the design and methodology of future clinical studies in this field in order
to improve racial and ethnic representation in these trials and improve population health equity.

11

METHODS
Study selection and methods for this meta research project followed the procedures outlined by
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020
Checklist and the Consolidated Standards for Reporting Trials (CONSORT) Flow Diagram.22,23
Given that this meta research project involved a critical appraisal and critique of previous
research studies and did not involve any direct clinical trials or new research on human subjects,
Institutional Review Board (IRB) approval was not required. Additionally, because my primary
outcome of interest involved patient demographic information and representation, effect
measures (such as risk or odds ratios), data synthesis methods, and certainty assessments were
out of scope for the purposes of this meta research project..

Eligibility Criteria
In 1998, The American Medical Association’s Council on Long Range Planning and
Development drafted a healthcare policy (H-350.974) declaring racial and ethnic disparities
to be a major public health problem.24 Part of their policy resolution included the
development of evidence-based performance measures to reduce health disparities across
various socioeconomic and racial/ethnic groups, including greater representation of people
of color in medicine and clinical trials. In order to assess whether recent clinical trials and
RCTs have effectively incorporated greater diversity in study recruitment, the database
searches in this meta research project were limited to that of RCTs and clinical trials
published in or after 1999 (one year after the policy’s inception) through 2021. With our
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population base being U.S. patients with PCOS-related infertility, these studies were limited
to English language studies conducted within the United States and therefore, excluded any
non-English studies conducted outside the U.S. This search strategy was also restricted to
only include full-text publications and excluded studies with pre-trial registries or pre-prints.

Inclusion Criteria
When considering search terms and search criteria for this meta research project, only
articles that focused on the primary health condition of PCOS-related infertility were
included. PCOS-related infertility can be defined and broken down into the following two
components: 1) PCOS is a condition that affects women of reproductive age, which is
defined as women who are biologically capable of conceiving children. This includes
adolescents who have reached pubertal maturation all the way to fertile adult women who
have not yet reached the stage of menopause. 2) This meta research project only focuses on
women who have been clinically diagnosed with Polycystic Ovary Syndrome and struggle
to conceive children naturally due to fertility-related complications. Furthermore, while
there are various methods and ways of treating PCOS-related infertility, this search strategy
was constrained to only include the four most common pharmacotherapy drug treatments,
which include: Clomiphene, Letrozole, Metformin, and Gonadotropins. Streamlining the
search to these four drug treatments ensures consistency across the various database
searches and helps to keep a more refined and focused search. Finally, as defined in our
study selection criteria, this meta research project only included RCTs and clinical trials
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published between the years of 1999-2021 that were written in English-language and
conducted in the United States.

Exclusion Criteria
In order to focus and optimize the results of this meta research project, there were various
study characteristics and terms that were excluded from the search strategy. First, given that
this research project focuses on PCOS-related infertility among women of reproductive age,
studies that included young people who have not yet reached pubertal maturation age and
post-menopausal women were excluded from this search. Additionally, while there are an
array of different drug treatments and interventions for the treatment of PCOS-related
infertility, this study has taken a focused review of the four most common pharmacotherapy
drug treatments of Clomiphene, Letrozole, Metformin, and Gonadotropins. As such, any
other pharmacotherapy drug treatments outside of these four medications were excluded
from the search criteria. While the primary intervention involves pharmacotherapy drug
treatments, it is possible to encounter studies that also incorporate lifestyle modifications or
other non-drug treatment therapies as secondary interventions in treating PCOS-related
infertility, which were excluded from our study. Finally, non-clinical trials and non-RCT
studies published before 1999 and non-English studies conducted outside of the U.S. were
excluded, as well as any pre-trial registries, pre-prints without full-text publications, or
clinical trials in pre-publication phases.
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Information Sources
Working with public health advisors and trained medical librarians, I as a solo researcher
conducted searches for primary research studies across five expanded electronic databases
and registries, which included Ovid MEDLINE, PubMed, Scopus, Ovid Embase, and Web of
Science. The publication dates for study selection across all five search bases were restricted
to 1999 - 2021, as justified in the eligibility criteria above. The rationales for selecting each
database or registries are outlined as follows:
Ovid MEDLINE: Compiled by the U.S. National Library of Medicine, Ovid
MEDLINE is the world’s most comprehensive source of life sciences and biomedical
bibliographic information, containing publications from 1965 to present.25 Despite
similarities to PubMed, Ovid MEDLINE offers a more structured and flexible
interface, thus yielding more focused search results.
PubMed: Developed and maintained by the National Institutes of Health, PubMed is
a free and comprehensive literature search base, primarily across biomedical,
healthcare, and life sciences literature. With more than 33 million citations, abstracts,
and full-text journal articles, PubMed is one of the largest scientific databases in
medicine and healthcare, which will yield a high degree of relevant academic journal
articles for my selected research topic.26 Furthermore, PubMed has a very streamlined
and user-friendly search experience due to its automatic term mapping feature, has
excellent system response speeds, and is widely accessible to both researchers and the
general public.
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Scopus: Launched in 2004, Scopus is the largest abstract and citation database for
peer-reviewed literature in the fields of science, technology, medicine, social
sciences, arts, and humanities.27 Through institutional access via Yale University, this
database will allow for an expansive and comprehensive search for relevant studies
within the defined inclusion and exclusion criteria.
Ovid Embase: Produced by Elsevier, Ovid Embase is a biomedical and
pharmacological database, yielding over 32 million abstracts, indexes, and full-text
articles.28 This database utilizes Emtree to index full-text content and search terms in
order to uncover all relevant and current publications. With my thesis project
involving studies of pharmacotherapy drug treatments in treating infertility-related
PCOS, Ovid Embase will serve as a key database for searching studies involving
pharmacological treatments.
Web of Science: Owned and produced by Clarivate, Web of Science is a
multi-disciplinary research and citation database that allows users to search across
almost 1.9 billion cited references and over 171 million records across a wide range
of medical, social science, and humanities disciplines.29

Search Strategies
Comprehensive and expansive literature searches were conducted via Ovid MEDLINE,
PubMed, Scopus, Ovid Embase, and Web of Science databases. Through institutional student
access through the Harvey Cushing/John Hay Whitney Medical Library at Yale University, I
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was granted expanded access to a wide range of biomedical publications to support this
meta research project. In building my database search strategy, I gained inspiration from a
research publication by author Showell et al. in their 2018 publication, Inositol for Subfertile
Women with Polycystic Ovary Syndrome.30

While each database contains unique search and filtering techniques (such as the use of Map
Term to Medical Subject Heading (MeSH) in Ovid MEDLINE and PubMed, and the use of
Emtree for controlled vocabulary and full-text indexing in Ovid Embase), a general protocol
was followed in order to ensure search consistency across all databases. First, a
comprehensive search across all databases involved searching for the main condition of
interest, Polycystic Ovary Syndrome. When applicable, I refined this search to include
title/abstract, keyword, or text word searches of this term in order to retrieve more focused
results. This also included the various or alternative iterations or abbreviations of the term,
disease synonyms, and relevant exploded MeSH entry terms. Such examples included
disease abbreviations “PCOS,” “PCOD,” or the formal medical terminology of the
condition, “Stein-Leventhal Syndrome.” Next, searches for each of the four major
pharmacotherapy drug treatments (Clomiphene, Letrozole, Metformin, and Gonadotropins)
were conducted. In order to capture the maximum possible studies, I also searched for these
drug treatment terms as medical subject headings via MeSH or Emtree when the drug
treatment was part of a controlled vocabulary, as well as keyword and text word searches.
Additionally, searches in all fields were conducted for the terms ‘ovulation,’ ‘ovulation
induction,’ ‘fertility,’ and ‘infertility’ in order to identify studies that focus on PCOS
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patients that suffer from infertility. Depending on the database, I either searched for
‘randomized controlled trials’ and ‘clinical trials’ as well as any relevant synonyms or
abbreviations of the term, or I applied a filter to these studies following the conclusion of
my search. I also excluded all studies that were conducted on animal subjects and only
included studies that focused on human subjects. A date filter for studies conducted between
1999 - 2021 was applied, as well as a filter for English language studies. The boolean
operators ‘AND’/’OR’/’NOT’ were used to combine the above search strategies to generate
the final search strategy outlined in Appendices A-E below. The above search strategies for
the five databases were conducted on December 3, 2021 and are accurate to this date. In
sum, 303 studies were identified in Ovid MEDLINE, 386 studies were identified in
PubMed, 1,866 studies were identified in Scopus, 47 studies were identified in Ovid
Embase, and 281 studies were identified in Web of Science. This resulted in a total
combined pool sum of 2,883 studies to be further filtered through.

Study Selection Process
After compiling a preliminary list of 2,883 studies from the initial search strategy above, I
as an independent researcher leveraged a systematic process to select studies to be included
in the final review. Figure 1 below provides a visual outline of this study selection process
and and is explained in greater detail in the following steps:
1. EndNote X9 was downloaded to be used as a reference and citation manager tool
to streamline the screening and selection of studies to be included in the final
meta research project. EndNote X9 is the preferred citation manager platform due
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to its robust and comprehensive information sourcing from individual studies, its
advanced functions such as auto-complete, edit/create your own filters, and the
many customizable fields, displays, and options. Furthermore, EndNote X9
supports the direct export of references directly from the individual database sites
into the citation manager, and also allows users to manually upload any additional
citations. The ‘find full text or PDF’ feature also allows for available PDF
documents or links to full-text web publications to be linked directly to EndNote
X9 for easy access and referencing.

2. After conducting the search strategies outlined in Appendices A-E and identifying
the 2,883 eligible studies, I downloaded and exported the references of these
studies into EndNote X9. The ‘remove duplicates’ feature in EndNote X9 was
used to automatically remove identical studies that were identified across multiple
databases. If duplicative studies still remained, I manually removed them from the
software. This filtering step removed 931 duplicate studies, leaving 1,952
remaining studies for further screening.

3. This stage in the filtering process involved a full screening of the title/abstract of
the 1,952 remaining de-duplicated studies. While non-RCT and non-clinical trial
studies should have been filtered out during the initial search strategy in the five
different database searches, I manually ensured accuracy and removed any studies
that did not fall within this inclusion criteria. Additionally, I manually removed
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any studies conducted outside of the U.S., published outside the years of 1999 2021, were not written in English language, and involved non-human subjects. In
addition, studies that did not include the four primary drug treatments of interest
(Clomiphene, Letrozole, Metformin, or Gonadotropins) were removed. Finally,
studies whose primary outcome did not focus on PCOS-related infertility (such as
insulin resistance, diabetes management, miscarriage rates, etc.) were also
removed. This resulted in the exclusion of 1,581 studies, leaving 371 remaining
studies for additional screening and appraisal.

4. From the remaining 371 remaining studies, I conducted a full-text screening of
each study and manually removed any studies that did not meet the inclusion and
exclusion criteria. During this stage of the screening, studies whose primary
and/or secondary interventions included additive external drug treatments (such as
Metformin in combination with Pioglitazone; or Clomiphene in combination with
oral contraceptives) were excluded. Additionally, studies whose primary or
secondary interventions included non-drug treatments, such as dietary
interventions, physical exercise, meditation therapy, or surgery, were removed.

5. After conducting a full-text analysis of all remaining studies, 8 studies were
included for final research analysis in this meta-research project.
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Figure 1: CONSORT diagram outlining the study selection process
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Data Collection Process
After conducting independent and separate study searches in the five electronic databases
and registries (including Ovid MEDLINE, PubMed, Scopus, Ovid Embase, and Web of
Science), I exported and managed all studies in EndNote X9 - Clarivate’s online citation and
reference manager to de-duplicate citations, screen the titles, abstracts, and full-text of
papers, and extract important and relevant data.31 Despite being an independent researcher
for this meta-research project, I leveraged partnerships with public health advisors and
trained medical library staff at the Yale School of Public Health to ensure the data collection
process was conducted accurately and efficiently.

Data Items
In order to assess individual study characteristics for each of the final 8 studies, Table 1
below includes a summary of each publication, as well as demographic information of the
study participants to be critically assessed in the results section. Each independent study has
its own row in the table matrix. The table below includes information about the primary
author, year of publication, study title, study design, study location, sample size, participant
demographics (including age, BMI, and race/ethnicity), primary/secondary interventions,
and primary/secondary outcomes. The study findings from each of the 8 studies will be
reported in a separate table in the results section.
The study characteristics table includes basic publication information, such as the name of
the primary author, the year the study was published, and the title of the study. The table
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also reports on study characteristics, such as the study design, study location, sample size,
and the participant demographics of the study, including factors such as age, BMI, and
race/ethnicity. The primary and/or secondary interventions, including the drug treatments
used in these studies are reported under the ‘primary/secondary interventions’ column, along
with primary/secondary outcomes in the final column.
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Table 1: Summary of Reviewed Studies
Author &
Year
Aubuchon
et al.
(2009).32

Cataldo et al.
(2008).33

Title

Study Design

Metformin Does
Not Improve the
Reproductive or
Metabolic Profile
in Women with
Polycystic Ovary
Syndrome (PCOS)

Randomized,
double-blind,
placebo
controlled
crossover
clinical trial

Extended-Release
Metformin Does
Not Reduce the
Clomiphene
Citrate Dose
Required to
Induce Ovulation
in Polycystic
Ovary Syndrome

Prospective,
double-blind,
placebo
controlled
multicenter
clinical trial

Study
Location
General
Clinical
Research
Center
(GCRC) at the
Albert
Einstein
College of
Medicine
(Bronx, NY)

Data
gathered
from
multiple
academic
medical
centers in
the U.S.
(locations
not
specified)

Sample Size

Participant Demographics

8 women
diagnosed
with PCOS (4
women
randomly
assigned to
intervention
group, 4
women
assigned to
control group)

Age Range: 18-38; mean age
of 25.6 ± 3.0 years

418 women
with PCOS and
elevated
serum
testosterone
(n = 209
women
randomized to
intervention
group, n = 209
women
randomized to
control group)

Age Range:
● Intervention Group: 28.3
± 4.0
● Control Group: 27.9 ± 4.0

Mean Weight: 98.5 ± 24.4kg;
BMI: 37.3 ± 9.6 kg/m2.
Race/Ethnicity: 5 African
American participants, 2
Caucasian participants, 1
Southeast Asian participant

BMI:
● Intervention Group: 34.2
± 8.4
● Control Group: 36.0 ± 8.9
Race/Ethnicity: Not reported

Primary/Secondary
Interventions
Intervention Group: 8 week
treatment of Metformin
(administered in a stepwise
fashion; starting at
500mg/week and increasing
by 500mg/week until
maximum dose of 2000mg
daily was achieved)

Primary/Secondary
Outcomes
Primary Outcome: To
determine whether
metformin promotes
folliculogenesis
(maturation of the
ovarian follicle) through a
rise in FSH levels among
women with PCOS.

Control Group: Placebo pills
administered in the same
stepwise fashion as the
Metformin intervention
group

Secondary Outcomes:
Weight/BMI status,
glucose use, suppression
of endogenous glucose
production, FFA, lipids,
androgens, urinary
pregnanediol glucuronide
(Pdg) elevation, LH
secretion, and SHBG
Primary Outcome: To
determine if
co-treatment with
Metformin XR can lower
the threshold dose of
clomiphene needed to
induce ovulation in
women with PCOS.
Ovulation was confirmed
by a serum progesterone
more than or equal to
5ng/ml, drawn every 1-2
weeks

Intervention Group:
Clomiphene Citrate at 50mg
daily for 5 days (increased to
100 or 150mg if ovulation
was not achieved) PLUS
metformin XR (100mg, twice
daily); continued for up to 30
weeks (6 ovulation cycles) or
until first pregnancy
Control Group: Clomiphene
Citrate at 50mg daily for 5
days (increased to 100 or
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Khorram
et al.
(2006).34

Legro et al.
(2007).35

Two Weeks of
Metformin
Improves
Clomiphene
Citrate-Induced
Ovulation and
Metabolic
Profiles in
Women with
Polycystic Ovary
Syndrome

Clomiphene,
Metformin, or
Both for Infertility
in the Polycystic
Ovary Syndrome

Randomized
prospective
control trial

Harbor-UCLA
Medical
Center
(Torrance,
California)

31 women
with
PCOS-related
infertility (n =
16 women
randomized to
intervention
group, n = 15
randomized to
control group)

Age Range:
● Intervention Group: 28.4
± 0.78
● Control Group: 28 ± 1.1
BMI:
● Intervention Group: 35.3
± 0.99
● Control Group: 38.8 ± 1.6
Race/Ethnicity:
● Intervention Group: 15
Hispanic, 1 Caucasian
● Control Group: 14
Hispanic, 1 African
American

Randomized
control trial

Department
of Obstetrics
and
Gynecology
at
Pennsylvania
State
University
College of
Medicine

626 infertile
women with
PCOS (n = 209
in cohort 1, n
= 208 in
cohort 2, n =
209 in cohort
3)

Age Range:
● Clomiphene Group: 27.9
± 4.0
● Metformin Group: 28.1 ±
4.0
● Combination Therapy
Group: 28.3 ± 4.0
BMI:
● Clomiphene Group: 36.0
± 8.9
● Metformin Group: 35.6 ±
8.5
● Combination Therapy
Group: 34.2 ± 8.4
Race/Ethnicity:

150mg if ovulation was not
achieved) PLUS a placebo pill
Intervention Group: Study
subjects were prescribed
500mg of Metformin three
times a day, given on cycle
days 1-14 (cycle day 1 = first
day of menses) in
combination with
Clomiphene Citrate (100mg)
per day taken on days 5-9 of
cycle. Intervention lasted 2
weeks
Control Group: Patients were
prescribed Clomiphene
Citrate (100mg/day) on cycle
days 5-9 only. Intervention
lasted 2 weeks
Cohort 1: Clomiphene Citrate
(50mg tablets) plus placebo;
one tablet a day for 5 days,
beginning on day 3 of
menses
Cohort 2: Metformin XR
(500mg tablets) plus
placebo; taken in stepwise
increments until maximum
dose of 2 tablets twice a day
was achieved
Cohort 3: Combination
Metformin XR (500mg
tablets); taken in stepwise
increments until maximum

Primary Outcome:
Ovulation as determined
by serum P, serum
insulin, and total and free
T.

Primary Outcome: To
assess the efficacy of
Clomiphene Citrate,
Metformin XR, or a
combination treatment
of Metformin XR plus
Clomiphene Citrate on
live birth rates
Secondary Outcomes:
Conception, pregnancy,
rates of pregnancy loss,
singleton birth, and
ovulation (a serum
progesterone level above
5ng per milliliter during a
cycle)
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● Clomiphene Group:
○ White: 147/209
(70.7%)
○ Hispanic/Latino:
53/209 (25.4%)
○ Black: 37/209 (17.8%)
○ Asian: 5/209 (2.4%)
○ American
Indian/Alaska Native:
21/209 (10.1%)
○ Native
Hawaiian/Pacific
Islander: 1/209
(0.5%)
● Metformin Group:
○ White: 140/208
(67.6%)
○ Hispanic/Latino:
61/208 (29.3%)
○ Black: 40/208 (19.3%)
○ Asian: 5/208 (2.4%)
○ American
Indian/Alaska Native:
27/208 (13%)
○ Native
Hawaiian/Pacific
Islander: 0/208 (0%)
● Combination Therapy
Group:
○ White: 148/209
(71.2%)
○ Hispanic/Latino:
50/209 (23.9%)
○ Black: 32/209 (15.4%)
○ Asian: 7/209 (3.4%)

dose of 2 tablets twice a day
was achieved; PLUS
Clomiphene Citrate (50mg
tablets); one tablet a day for
5 days, beginning on day 3 of
menses
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Legro et al.
(2014).36

Letrozole Versus
Clomiphene for
Infertility in the
Polycystic Ovary
Syndrome

Double-blind,
randomized
control trial

Department
of Obstetrics
and
Gynecology
at
Pennsylvania
State
University
College of
Medicine

750 women
with
PCOS-related
infertility (n =
376
randomized to
Clomiphene
Group, n = 374
randomized to
Letrozole
Group)

○ American
Indian/Alaska Native:
24/209 (11.5%)
○ Native
Hawaiian/Pacific
Islander: 0/209 (0%)
Age Range:
● Clomiphene Group: 28.8
± 4.0
● Letrozole Group: 28.9 ±
4.5
BMI:
● Clomiphene Group: 35.1
± 9.0
● Letrozole Group: 35.2 ±
9.5
Race/Ethnicity:
● Clomiphene Group:
○ White: 302/376
(80.3%)
○ Black: 44/376 (11.7%)
○ Asian: 12/376 (3.2%)
○ Mixed Race: 12/376
(3.2%)
○ Hispanic or Latino:
68/376 (18.1%)
● Letrozole Group:
○ White: 288/374
(77%)
○ Black: 56/374 (15%)
○ Asian: 12/374 (3.2%)
○ Mixed Race: 15/374
(4.0%)

Intervention Group 1: 376
women with PCOS-related
infertility received
Clomiphene Citrate (50mg
daily) in permuted blocks of
2, 4, or 6, beginning on cycle
day 3 for 5 days and lasting
up to five menstrual cycles. If
patient was non-responsive
to treatment, dose was
increased (max dose of
150mg). Couples were
instructed to have sexual
intercourse 2-3 times per
week and keep an
intercourse diary

Primary Outcome: Live
birth rates during the
treatment period
Secondary Outcomes:
Ovulation rates,
pregnancy loss among
women who conceived,
conception rates among
subjects who ovulated,
and congenital anomalies

Intervention Group 2: 374
women with PCOS-related
infertility received Letrozole
(2.5mg daily) in permuted
blocks of 2, 4, or 6, beginning
on cycle day 3 for 5 days and
lasting up to five menstrual
cycles. If patient was
non-responsive to treatment,
dose was increased (max
dose of 7.5mg). Couples
were instructed to have
sexual intercourse 2-3 times
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Mejia et al.
(2019).37

A Randomized
Controlled Trial of
Combination
Letrozole and
Clomiphene
Citrate or
Letrozole Alone
for Ovulation
Induction in
Women with
Polycystic Ovary
Syndrome

Randomized
control trial

Two clinic
sites at
academic
medical
centers in
the U.S.

70 women
with
PCOS-related
infertility (n =
35 randomized
to Letrozole
treatment
group, n = 35
randomized to
Letrozole +
Clomiphene
treatment
group)

○ Hispanic or Latino:
60/374 (16%)
Age Range:
● Letrozole Group: 31 ± 3.9
● Letrozole + Clomiphene
Group: 30 ± 4.4
BMI:
● Letrozole Group: 33 ± 8.7
● Letrozole + Clomiphene
Group: 34 ± 7.0
Race/Ethnicity:
● Letrozole Group:
○ White: 29/35 (83%)
○ Black: 2/35 (6%)
○ Asian: 1/35 (3%)
○ Hispanic/Latino: 2/35
(6%)
○ Mixed Race: 1/35
(3%)
● Letrozole + Clomiphene
Group:
○ White: 30/35 (86%)
○ Black: 1/35 (3%)
○ Asian: 1/35 (3%)
○ Hispanic/Latino: 2/35
(6%)
○ Mixed Race: 1/35
(3%)

per week and keep an
intercourse diary
Cohort 1: 35 women with
PCOS-related infertility
received Letrozole (2.5mg)
on cycle days 3-7 for one
treatment cycle
Cohort 2: 35 women with
PCOS-related infertility
received Letrozole (2.5mg) +
Clomiphene (50mg) on cycle
days 3-7 for one treatment
cycle

Primary Outcome:
Ovulation, defined as
mid-luteal progesterone
level of >3 ng/mL
Secondary Outcomes:
● Conception
● Clinical Pregnancy
● Live Birth Rates
● Singleton Birth
● Pregnancy Loss
● Size and number of
developing follicles
on cycle days 12-14
ultrasound
● Endometrial
thickness on cycles
days 12-14
ultrasound
● Adverse events
related to the study
medications
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Stadtmauer
et al.
(2011).38

Vandermolen
et al.
(2001).39

The Impact of a
GonadotropinReleasing
Hormone
Antagonist on
Gonadotropin
Ovulation
Induction Cycles
in Women with
Polycystic Ovary
Syndrome: A
Prospective
Randomized
Study

Prospective,
randomized
control study

Metformin
Increases the
Ovulatory Rate
and Pregnancy
Rate From
Clomiphene
Citrate in Patients
with Polycystic
Ovary Syndrome
who are Resistant
to Clomiphene
Citrate Alone

Randomized,
double-blind,
placebo
controlled
trial

Eastern
Virginia
Medical
School in
Norfolk,
Virginia

Multi-center
study across
three
academic
institutions
in Virginia
and Missouri

98
anovulatory
women with
PCOS who
underwent
154
gonadotropin
ovulation
induction
cycles
randomly
allocated to 3
treatment
groups:

26
anovulatory
women with
PCOS who
were resistant
to Clomiphene
(n = 11
randomized to
Metformin
treatment
group, n = 14
randomized to
Placebo
treatment
group)

Age Range:
● Group 1 (Follistim): 29.9 ±
4.2
● Group 2 (Follistim +
Ganirelix if FS≳13mm):
30.8 ± 3.9
● Group 3 (Follistim +
Ganirelix): 30.5 ± 4.4
BMI:
● Group 1 (Follistim): 32.2 ±
8.5
● Group 2 (Follistim +
Ganirelix if FS≳13mm):
29.9 ± 7.5
● Group 3 (Follistim +
Ganirelix): 29.0 ± 7.2
Race/Ethnicity: Not reported
Age Range:
● Metformin Group: 29 ±
1.2
● Placebo Group: 30 ± 1.0
BMI:
● Metformin Group: 37.6 ±
4.3
● Placebo Group: 38.4 ± 2.2
Race/Ethnicity: Not reported

Primary Intervention:
Gonadotropin medication
regimen used for ovulation
induction:
● Group 1: n = 50
randomized to Follistim
treatment group
● Group 2: n = 51
randomized to Follistim
+ Ganirelix if FS≳13mm
● Group 3: n = 41
randomized to Follistim
+ Ganirelix

Primary Outcomes:
● Per cycle clinical
pregnancy rate (CPR)
● Live birth rate (LBR)

Cohort 1: 11 anovulatory
women with PCOS were
randomized to receive
Metformin treatment
(500mg three times daily for
7 weeks)

Ovulation and Pregnancy
Rates

Secondary Outcomes:
● Total gonadotropin
dose
● Days of stimulation
● Serum LH
● Peak E2
● Premature
luteinization rate

Cohort 2: 14 anovulatory
women with PCOS were
randomized to receive
placebo, instructed to take
three times daily for 7 weeks
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Risk of Bias Assessment
In order to assess the risk of bias in the included eight studies, this meta research project
leveraged the Cochrane Risk of Bias Tool for Randomized Trials (RoB 2). 40 RoB 2 is the
preferred and recommended tool to assess risk of bias in RCTs and clinical trials due to the
streamlined and fixed set of assessment domains used to determine whether studies present
a high, medium, or low risk of bias. The Cochrane website lists seven domains by which to
assess bias, which includes: random sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome assessment, incomplete outcome data,
selective reporting, and other potential biases.41 A risk of bias table as outlined below in
Table 2 highlights each of the eight studies and the risk of potential biases across each of the
seven domains. Studies found to have a low risk of bias are represented by green circles.
Meanwhile, studies with a high risk of bias are represented by red circles, and studies whose
methodology presents unclear conclusions on risk of bias are represented by yellow circles.
It is important to note that by performing this risk of bias assessment as a solo researcher,
this presents some significant limitations, as I do not have the capability to confer or
collaborate with a team of researchers and colleagues to validate these assertions. However,
by following a systematic process of assessing bias in studies, this meta research project
aims to maintain the validity and quality of this review process. Given that the primary
objective of this meta research project is to assess patient demographic representation in
these clinical trials, studies with domains that presented a potential risk for bias were still
included in the final inclusion criteria but will be critiqued further relative to secondary
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outcomes and how they may influence factors such as ovulation, pregnancy rates, and
fertility.

Table 2: Risk of Bias Summary Assessment Table
Random
sequence
generation
(Selection
Bias)

Allocation
concealment
(Selection
Bias)

Blinding of
participants
(Performance
Bias)

Blinding of
outcome
assessment
(Detection
Bias)

Incomplete
outcome data
(Attrition Bias)

Selective
reporting
(Reporting
Bias)

Other Bias

Aubuchon et
al. (2009)
Cataldo et al.
(2008)
Khorram et
al. (2006)
Legro et al.
(2007)
Legro et al.
(2014)
Mejia et al.
(2019)
Stadtmauer et
al. (2011)
Vandermolen
et al. (2001)

Legend:

= Low risk of bias

= Unclear risk of bias

= High risk of bias
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RESULTS
A total of 8 randomized controlled trials and clinical trials published between the years of 1999 2021 were included in this final meta research analysis. These 8 studies, their statistical analyses
and study findings are reported below in Table 3. Across the 8 studies, 2,027 women with
PCOS-related infertility were recruited, randomized, treated, and assessed for outcomes such as
rates of ovulation, pregnancy, and live birth rates. All 8 studies were conducted within either
clinical research centers or academic medical centers across the U.S. in locations such as New
York, California, Pennsylvania, Virginia, and Missouri. Findings from these eight studies are
subsequently stratified based on the following outcomes:

Participant Demographics
Of the eight assessed studies, three studies (Cataldo et al., Stadtmauer et al., and
Vandermolen et al.) did not report the race or ethnicity of the enrolled participants. First,
while the Cataldo et al. study did provide a table for baseline characteristics of the two
treatment groups (Clomiphene-only versus Clomiphene plus Metformin), the baseline
characteristics only included information about participants’ age, BMI, insulin/glucose
levels, and various metrics on infertility such as previous history of infertility, conception,
live birth rates, etc. Similarly, the Stadtmauer et al. study also provided a table for patient
demographics, yet provided no information about participant race or ethnicity. Their
demographic characteristics simply included participants’ age, BMI, and baseline FSH, LH,
and E2 levels. Finally, the Vandermolen et al. study provided a table for patient
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characteristics both before and after treatment, but similarly to the previous two studies,
only included characteristics about the participants’ age, weight, BMI, insulin/glucose
levels, and various hormone levels.
While the remaining five studies did report on patient demographic information for each of
their study subjects, the degree of racial/ethnic representation varied significantly. Three
studies (Legro et al. (2007), Legro et al. (2014), and Mejia et al.) had an overwhelmingly
white population base. First, while the Legro et al. (2007) study ensured that the baseline
characteristics and demographic representation across the three treatment groups were as
similar as possible, all three groups had a disproportionate representation of white women
(70.7%, 67.6%, and 71.2% white in each cohort group, respectively). Hispanic or Latino
women had the next highest representation, but at much lower percentages (25.4%, 29.3%,
and 23.9% in each cohort group, respectively), followed by Blacks (17.8%, 19.3%, and
15.4%, respectively), American Indian or Alaska Native (10.1%, 13.0%, and 11.5%,
respectively), Asian (2.4%, 2.4%, 3.4%, respectively), and Native Hawaiian or Pacific
Islander (0.5%, 0%, and 0%, respectively).1 Next, the Legro et al. (2014) study also had a
disproportionate race/ethnicity ratio. Across the two comparison groups (Clomiphene group
versus Letrozole group), the majority of patients identified as white (80.3% and 77.0%,
respectively), followed by Hispanic/Latinos (18.1% and 16%, respectively), Blacks (11.7%
and 15%, respectively), Asian (3.2% and 3.2%, respectively), and mixed race (3.2% and
4%, respectively).1 Finally, the Mejia et al. study had perhaps the most disproportionate
racial/demographic representation among the recruited participants. Across the two

Summed percentages across all racial and ethnic groups may sum to greater than 100% because participants
were allowed to choose more than one racial category
1
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comparison groups (Letrozole versus Letrozole + Clomiphene), an overwhelming majority
of participants identified as White (83% and 86%, respectively), followed by Hispanic or
Latino (6% and 6%, respectively), Blacks (6% and 3%, respectively), Asians (3% and 3%,
respectively), and mixed race (3% and 3%, respectively).
On the contrary, were two studies whose participant demographics involved predominantly
women of color. First, the Aubuchon et al. study included 5 Black participants, 2 white
participants, and 1 Southeast Asian participant. Finally, the Khorram et al. study recruited
participants that all identified as women of color. Across the two comparison groups
(Metformin group versus Clomiphene group), the majority of participants identified as
Hispanic/Latino (94% and 93%, respectively), followed by one person who identified as
white in the Metformin group (6%), and one person who identified as Black in the
Clomiphene group (7%).

Ovulation Outcomes Compared Across Race/Ethnicity
Six of the eight studies focused on rates of ovulation as either their primary or secondary
outcomes. Of these six studies, four studies assessed whether additive drug treatments taken
in combination are more efficacious than single drug treatments in improving rates of
ovulation among women diagnosed with PCOS. First, the Cataldo et al. study assessed
whether a combination of Clomiphene Citrate in combination with Metformin ER could 1)
improve ovulation induction, and 2) lower the threshold dose of clomiphene needed to
induce ovulation. The study found that 83% of participants who received the combination
therapy ovulated, while 75% of participants who received just Clomiphene Citrate plus a
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placebo ovulated (p = 0.04). However, the study also found that The frequency distribution
of the lowest clomiphene dose (50, 100, or 150 mg daily) resulting in ovulation was
indistinguishable between the two treatment groups (Ovulation in 52.2% in intervention vs.
45.5% in control for 50mg dose, ovulation in 20.6% in intervention vs. 18.1% in control for
100mg dose, ovulation in 5.7% in intervention vs. 8.1% in control for 150mg dose; p =
0.47). Mirroring a similar study design, the Khorram et al. study assessed whether
participants who received a combination of Metformin plus Clomiphene Citrate experienced
distinguishable rates of ovulation in comparison with patients who were prescribed
Clomiphene Citrate alone. The findings illustrated that 44% of patients who received the
combination drug treatments ovulated, while only 6.7% of participants who received
Clomiphene Citrate alone ovulated (p = 0.037). The Legro et al. (2007) study involved a
triple-armed randomized controlled trial, whereby patients either received Clomiphene
alone, Metformin alone, or a combination of the two drug treatments at the same time. The
findings from this study illustrated that participants in the Clomiphene only group ovulated
an average of 2.22 times during the study cycle ± 1.87, while participants in the
Metformin-only group ovulated an average of 1.43 times ± 1.72, and the combination drug
therapy group ovulated an average of 2.80 times ± 2.04; p<0.001 for all three groups.
Finally, the Mejia et al. study assessed whether Letrozole alone or in combination with
Clomiphene Citrate would increase ovulation rates. They found that 42.9% of individuals
randomized to Letrozole treatment alone ovulated, while 77.1% of individuals randomized
to the Letrozole + Clomiphene Citrate treatment group ovulated (p = 0.007). In all four of
these studies, the researchers were able to assert that combination drug treatments were
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statistically significantly more efficacious than single-drug treatments in improving
ovulation rates among women with PCOS. Across these four studies that assessed additive
drug treatments, none of the studies stratified their findings across race or ethnicity groups.

Two additional studies also assessed ovulation outcomes, but compared solo drug treatments
- either against a different drug treatment, or against a placebo. First, the Legro et al. (2014)
study assessed whether Letrozole or Clomiphene was more efficacious in improving
ovulation rates among women with PCOS. The study concluded that 76.6% of women who
were randomized to the Clomiphene group ovulated, while 88.5% of women who were
randomized to the Letrozole group ovulated (p<0.001). Additionally, the Vandermolen et al.
study assessed whether Metformin could improve the ovulatory rate of women with
Clomiphene Citrate-resistant PCOS compared to a placebo treatment. The study found that
75% of women who received the Metformin treatment ovulated, while 27% of the women
who received the placebo treatment ovulated (p = 0.02). It is clear that neither of these two
studies stratified their results across race or ethnicity.

Conception Outcomes Compared Across Race/Ethnicity
Four out of the eight studies assessed rates of conception among patients who ovulated. Of
these four studies, the Mejia et al.’s findings were found to not be statistically significant (p
= 0,709). Of the three remaining studies, two studies assessed whether additive drug
treatments taken in combination were more efficacious than single drug treatments in
improving conception rates among these women with PCOS. First, the Khorram et al. study
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found that five study subjects in the combination Clomiphene plus Metformin group
conceived, while none of the study subjects in the Clomiphene group alone conceived (p =
0.043). Additionally, the Legro et al. (2007) study found that 39.5% of study subjects who
received Clomiphene treatment ovulated (p = 0.002), compared to 21.7% who were
randomized to the Metformin treatment group (p = 0.002), and 46% randomized to the
combination therapy group of both Clomiphene plus Metformin (p<0.001). Neither of these
studies stratified their results across race or ethnicity groups.
The Legro et al. (2014) study assessed conception rates among study subjects who ovulated
between solo-drug treatment comparison groups. They found that 35.8% of study subjects
who received Clomiphene alone ovulated, while 46.5% of study subjects who received
Letrozole alone ovulated (p = 0.007). Similar to the Khorram et al. and Legro et al. (2007)
studies above, the Legro et al. (2014) study did not stratify their results across race or
ethnicity groups.

Pregnancy Outcomes Compared Across Race/Ethnicity
Five of the eight studies assessed pregnancy outcomes across the various treatment groups.
Among these five studies, both the Mejia et al. and the Stadtmauer et al. studies produced
pregnancy outcomes that were not statistically significant (p = 0.356 and p = 0.16,
respectively). Of the remaining three studies, the Legro et al. (2007) study was the only trial
to assess pregnancy outcomes across single versus additive drug treatments. They found that
23.9% of women who were randomized to the Clomiphene treatment group became
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pregnant, compared to 8.7% for those randomized to Metformin, and 31.1% randomized to
the combination therapy group of both Clomiphene plus Metformin (p<0.001). Meanwhile,
the Legro et al (2014) study compared Clomiphene versus Letrozole in assessing pregnancy
outcomes. This study found that 21.5% of women randomized to the Clomiphene treatment
group became pregnant, compared to the 31.3% randomized to the Letrozole treatment
group (p = 0.003). Finally, the Vandermolen et al. study assessed pregnancy rates across the
Metformin versus placebo intervention groups. They concluded that 55% of individuals
randomized to the Metformin treatment group became pregnant, compared to 7% who were
randomized to the placebo group (p = 0.02). Thorough analysis of these articles found that
none of the above studies reported or stratified findings across race or ethnicity metrics.

Live Birth Rate Outcomes Compared Across Race/Ethnicity
Four of the eight studies assessed live birth rate outcomes among women who became
pregnant. Among these four studies, the Mejia et al. and the Stadtmauer et al. studies
produced findings that were not statistically significant (p = 1.00 and p = 0.08, respectively).
The Legro et al. (2007) study assessed live birth rate outcomes across single versus additive
drug treatments and found that 22.5% of individuals randomized to receiving Clomiphene
treatment successfully had a live birth, yet this finding was found to be statistically
insignificant (p = 0.31). However, 7.2% of individuals randomized to the Metformin group
had a successful live birth, and 26.8% randomized to the combination therapy group
experienced a live birth; p<0.001 for both groups. Finally, the Legro et al. (2014) study
compared Clomiphene versus Letrozole treatments in assessing live birth rates. This study
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found that 19.1% of individuals randomized to Clomiphene-only experienced live birth,
while 27.5% of individuals randomized to Letrozole-only experienced live birth, p = 0.007.
None of the four above studies that assessed live birth rate outcomes stratified findings
across race or ethnicity metrics.
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Table 3: Statistical Findings, Study Results, and Study Conclusions of Reviewed Studies
Author & Year

Title

Aubuchon et al.
(2009)

Metformin Does Not
Improve the Reproductive
or Metabolic Profile in
Women with Polycystic
Ovary Syndrome (PCOS)

Statistical Findings & Study Results
Urinary FSH levels (4.3 ± 1.4 versus 4.7 ± 1.68 U/g, p =
0.48), and LH levels (7.1 ± 5.2 versus 7.5 ± 3.6 U/g, p =
0.26), and Pdg (0.92 ± 0.69 versus 1.1 ± 1.0 µg/mg, p =
0.40) did not differ significantly between the metformin
and the placebo groups
Two participants ovulated on both placebo and metformin
treatments
Urinary gonadotropins were not statistically significantly
different before and after metformin, whether or not the
participants who ovulated were included

Study Conclusions & Racial Stratification of Findings
Short-term, high-dose metformin has minimal effects on
metabolic markers and reproductive hormones in a small
sample of obese women with PCOS
The study hypothesis that metformin (via increased insulin
sensitivity and SHBG), reduces free sex steroids and induces a
compensatory FSH rise
There was minimal effectiveness of metformin in promoting
insulin sensitivity
Study results were not stratified by racial/ethnic group

Serum sex steroid response to metformin and placebo
were not statistically significant (p > 0.16 for all secondary
outcomes).

Cataldo et al.
(2008)

Extended-Release
Metformin Does Not
Reduce the Clomiphene
Citrate Dose Required to
Induce Ovulation in
Polycystic Ovary
Syndrome

BMI-normalized biomarkers were not statistically
significant between metformin and placebo groups
At least one ovulation occurred in 174/209 subjects (83%)
in the clomiphene plus metformin group, and at least one
ovulation occurred in 157/209 subjects (75%) in the
clomiphene-only group (p = 0.04).
The frequency distribution of the lowest clomiphene dose
(50, 100, or 150 mg daily) resulting in ovulation was
indistinguishable between the two treatment groups
(Ovulation in 52.2% in intervention vs. 45.5% in control for
50mg dose, ovulation in 20.6% in intervention vs. 18.1% in
control for 100mg dose, ovulation in 5.7% in intervention
vs. 8.1% in control for 150mg dose; p = 0.47).

Patients who received the combination drug treatment of
Clomiphene plus Metformin had a greater rate of ovulation
than patients who received Clomiphene-only plus the placebo
treatment.
Metformin XR does not reduce the lowest dose of clomiphene
that induces ovulation in women with PCOS
Study results were not stratified by racial/ethnic group
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Khorram et al.
(2006)

Two Weeks of Metformin
Improves Clomiphene
Citrate-Induced Ovulation
and Metabolic Profiles in
Women with Polycystic
Ovary Syndrome

Both groups found a significant increase in the sex
hormone-binding globulin (SHBG) levels after treatment
on day 21 of the cycle, but the increment in SHBG in the
CC+Met group was significantly higher (p<0.05) than in
the CC-only group.

In obese patients with PCOS, two weeks of Metformin
treatment significantly reduces serum insulin and insulin
resistance and increases SHBG levels, resulting in an improved
response to Clomiphene Citrate
Study results were not stratified by racial/ethnic group

There was a significant decrease in fasting insulin
(p<0.025) and ratio of glucose to insulin (p<0.05) in the
CC+Met group, but not in the CC-only group.
On day 21, Serum P levels was significantly elevated in the
CC+Met group in contrast to the CC-only group (p = 0.015)
In the CC+Met group, 7/16 subjects (44%) ovulated,
whereas only 1/15 subjects (6.7%) ovulated in the CC-only
group (p = 0.037)

Legro et al.
(2007)

Clomiphene, Metformin,
or Both for Infertility in
the Polycystic Ovary
Syndrome

In the CC+Met group, 5 subjects conceived, whereas no
subjects in the CC-only treatment conceived (p = 0.043).
Live birth rates:
● Clomiphene Group: 47/209 (22.5%); p = 0.31
● Metformin Group: 15/208 (7.2%); p<0.001
● Combination Therapy Group: 56/209 (26.8%);
p<0.001
Number of ovulations (Mean ± SD):
● Clomiphene Group: 2.22 ± 1.87; p<0.001
● Metformin Group: 1.43 ± 1.72; p<0.001
● Combination Therapy Group: 2.80 ± 2.04; p<0.001
Pregnancy:
● Clomiphene Group: 50/209 (23.9%); p<0.001
● Metformin Group: 18/208 (8.7%); p<0.001
● Combination Therapy Group: 65/209 (31.1%);
p<0.001

Live birth rates were significantly lower in the Metformin
group than in either the Clomiphene or Combination Therapy
Group. Ovulation rates were significantly higher in the
combination group than in either the Clomiphene or
Metformin groups alone, however this did not translate into
an increase in live-birth rates among subjects who received
the combination therapy treatments. Rates of conception and
pregnancy were significantly higher in the Clomiphene and
Combined Therapy Group than in the Metformin group. These
findings show that Clomiphene is superior to metformin in
achieving live birth in women with PCOS-related infertility
Study results were not stratified by racial/ethnic group
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Legro et al.
(2014)

Letrozole Versus
Clomiphene for Infertility
in the Polycystic Ovary
Syndrome

Conception rates among subjects who ovulated:
● Clomiphene Group: 62/157 (39.5%); p = 0.002
● Metformin Group: 25/115 (21.7%); p = 0.002
● Combination Therapy Group: 80/174 (46.0%);
p<0.001
Live birth rates:
● Clomiphene Group: 72/376 (19.1%); p = 0.007
● Letrozole Group: 103/374 (27.5%); p = 0.007
Ovulation Rates:
● Clomiphene Group: 288/376 (76.6%); p<0.001
● Letrozole Group: 331/374 (88.5%); p<0.001
Pregnancy Rates:
● Clomiphene Group: 81/376 (21.5%); p = 0.003
● Letrozole Group: 117/374 (31.3%); p = 0.003

Women who received Letrozole had more cumulative live
births than those who received Clomiphene Citrate. The
cumulative ovulation rates were higher in those who received
Letrozole treatment than Clomiphene. There were no
significant between-group differences in pregnancy loss
between the two treatment groups. Conception rates among
subjects who ovulated were 10% higher in the Letrozole group
than the Clomiphene group.
Study findings/results stratified by race/ethnicity were not
reported

Pregnancy Loss Among Women Who Conceived:
● Clomiphene Group: 30/103 (29.1%); p = 0.65
● Letrozole Group: 49/154 (31.8%); p = 0.65
Conception rates among subjects who ovulated:
● Clomiphene Group: 103/288 (35.8%); p = 0.007
● Letrozole Group: 154/331 (46.5%); p = 0.007
Congenital Anomalies:
● Clomiphene Group: 1/66 (1.5%); p = 0.65
● Letrozole Group: 4/102 (3.9%); p = 0.65
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Mejia et al.
(2019)

A Randomized Controlled
Trial of Combination
Letrozole and Clomiphene
Citrate or Letrozole Alone
for Ovulation Induction in
Women with Polycystic
Ovary Syndrome

Rates of Ovulation:
● Letrozole Group: 15/35 (42.9%); p = 0.007
● Letrozole + Clomiphene Group: 27/35 (77.1%); p =
0.007

Women who received the combination treatment of Letrozole
and Clomiphene had a statistically significantly higher rate of
ovulation compared to individuals who received the letrozole
treatment alone.

Conception Rates:
● Letrozole Group: 3/35 (8.8%); p = 0.709
● Letrozole + Clomiphene Group: 4/35 (12.1%); p =
0.709

There were no statistically significant differences in
conception, pregnancy, and fecundity rates between the two
treatment groups. Significant adverse events related to the
treatments did not occur during the study. Participants in both
groups reported similar acceptability of side-effects

Clinical Pregnancy:
● Letrozole Group: 1/35 (2.9%); p = 0.356
● Letrozole + Clomiphene Group: 3/35 (9.1%); p =
0.356

Study results were not stratified by racial/ethnic group

Fecundity among those who ovulated:
● Letrozole Group: 3/14 (21%); p = 0.686
● Letrozole + Clomiphene Group: 4/25 (16%); p =
0.686
Live Birth Rates:
● Letrozole Group: 1/14 (7%); p = 1.00
● Letrozole + Clomiphene Group: 3/25 (12%); p = 1.00
There were no significant adverse events related to the
treatments during the course of the study
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Stadtmauer et
al. (2011)

Vandermolen et
al. (2001)

The Impact of a
Gonadotropin-Releasing
Hormone Antagonist on
Gonadotropin Ovulation
Induction Cycles in
Women with Polycystic
Ovary Syndrome: A
Prospective Randomized
Study

Metformin Increases the
Ovulatory Rate and
Pregnancy Rate From
Clomiphene Citrate in
Patients with Polycystic
Ovary Syndrome who are
Resistant to Clomiphene
Citrate Alone

Primary Outcomes:
● Per cycle clinical pregnancy rate (CPR); p = 0.16:
○ Group 1 (Follistim): 12/50 (24%)
○ Group 2 (Follistim + Ganirelix if FS≳13mm):
19/51 (37%)
○ Group 3 (Follistim + Ganirelix): 9/41 (22%)
● Live birth rate (LBR); p = 0.08:
○ Group 1 (Follistim): 10/50 (20%)
○ Group 2 (Follistim + Ganirelix if FS≳13mm):
18/51 (35%)
○ Group 3 (Follistim + Ganirelix): 7/41 (18%)
Secondary Outcomes:
Premature luteinization was highest in group 1 (21% vs.
1.8% in group 2 and 2.1% in Group 3). Group 3 had the
highest cancellation rate and cost without improving CPR
and LBR. No differences were
noted in peak serum E2, total gonadotropin dose, or days
of stimulation
Rates of Ovulation:
● Metformin Group: 9/12 (75%); p = 0.02
● Placebo Group: 4/15 (27%); p = 0.02
Pregnancy Rates:
● Metformin Group: 6/11 (55%); p = 0.02
● Placebo Group: 1/14 (7%); p = 0.02

While clinical pregnancy rates were the greatest in Group 2
compared to groups 1 and 3, the results were not statistically
significant. Similarly, live birth rates were highest in Group 2
compared to groups 1 and 3, but results were just out of
margins of statistical significance
Adding Ganirelix in a flexible protocol to gonadotropin OI
cycles in women with PCOS may be beneficial by decreasing
premature luteinization
Study results were not stratified by racial/ethnic group

In anovulatory women with PCOS who are resistant to
Clomiphene Citrate, Metformin was found to significantly
increase ovulation rates and pregnancy rates. These results
provide a rationale and justification for the use of Metformin
and Clomiphene Citrate treatment for obese Clomiphene
Citrate resistant women with PCOS before proceeding to
ovulation induction with gonadotropins or to in-vitro
fertilization/embryo transfer (IVF/ET). Furthermore, it is clear
that Metformin treatment is less expensive compared to
gonadotropins and IVF/ET.
Study results were not stratified by racial/ethnic group
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DISCUSSION
With knowledge that Polycystic Ovary Syndrome is a condition that tends to disproportionately
affect minority women of color, the primary objective of this meta research project was to
critically assess racial representation in the methodology and recruitment in randomized
controlled trials and clinical trials for studies on PCOS-related infertility. Across the eight studies
that were identified in the final search criteria, three studies (37.5%) failed to report the race or
ethnicity of the enrolled participants. Meanwhile, while five studies (62.5%) did provide
information about the patients’ racial and demographic characteristics, three of the studies
(37.5%) involved an overwhelming majority of white women, with women of color comprising a
very small proportion of the overall study population. While there were two studies (25%) whose
study recruitment involved predominantly women of color, these studies had a very small sample
size. The Khorram et al. study contained a total sample size of 31 participants, while the
Aubuchon et al. study had a total sample of 8 participants. While both of these studies recruited
predominantly women of color, it is unclear whether this was due to chance alone, or whether the
diversity of these individuals were intentionally recruited.
In assessing all eight of the included studies, none of the authors outlined the recruitment
methodology procedures nor sampling techniques leveraged when selecting participants for these
clinical trials. For the five studies who reported on patient demographics, the only information
provided was a baseline characteristics table, which outlined the facets such as the average age,
BMI, and race/ethnicity of the study subjects. However, the methods section for these individual
studies failed to provide an adequate explanation about the sampling techniques they deployed,
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or the rationale behind who they included in their sampling framework. Despite the fact that five
of the eight studies included information about patient demographics, none of these studies
stratified the primary or secondary results based on these racial or ethnic categories. As such,
when assessing the various outcome measures (such as ovulation rates, conception, and fertility
outcomes), it was impossible to discern whether these findings were representative of all
patients, or whether there were disparate outcomes across various patient demographic groups.
Despite efforts to ensure a high degree of evidence synthesis for this meta research project, this
study had some limitations. As a solo researcher, I had to contend with the challenges of
independently determining the best and optimal design for my study inclusion methodology,
including selecting which academic databases to leverage, outlining my search strategy with
consistency across all sites, and determining which studies to filter and screen during the
inclusion and exclusion phase. Traditionally, these types of review processes would be best
executed alongside a robust team of academic researchers, statisticians, database research
scientists, and subject matter experts - all of whom can work together to cross-validate decisions.
Additionally, this study was significantly limited by the fact that only 8 final studies survived the
inclusion/exclusion criteria to be included in the final assessment. As I navigated the process of
filtering through studies based on the defined inclusion and exclusion criteria, I realized that a
significant majority of the published studies across the five databases were conducted in
international contexts, such as China, India, Iran, Finland, and Saudi Arabia. While many of
these international studies did assess the four major pharmacotherapy drug treatments of interest
among women with PCOS-related infertility, it is clear that the racial and ethnic demographics of
individuals in the aforementioned countries are largely homogeneous. With the U.S. serving as a

46

melting pot of different cultures and ethnicities, including these homogeneous population groups
from international settings would not only be out of scope of this research question, but would
detract from our understanding of whether clinical trial recruitment strategies in the U.S. are
representative of the true population affected by PCOS-related infertility. Consequently, when
these international studies were filtered out, this left a very small final sample of studies to be
assessed in this meta research paper, which made generalizing findings rather difficult.
Another significant limitation that I encountered during this process was the fact that each of the
eight studies had different intervention and outcome measures. Given that my final inclusion
criteria included any combination of the pharmacotherapy drug treatments of Clomiphene,
Letrozole, Metformin, or Gonadotropins, there were no two studies that had the same study
methodology or design. For example, some studies assessed the role of additive versus singular
drug treatments on fertility-related outcomes (such as Clomiphene + Metformin vs. Clomiphene
alone), while other studies assessed a single drug treatment against a placebo. Therefore,
comparing results across these eight studies was difficult to accomplish.
It is clear that clinical trials and academic research studies in the U.S. are all required to follow a
strict set of protocols and procedures in order to ensure safety to study subjects, maintain strong
ethical procedures, and minimize sources of error and biases. Through metrics such as
Cochrane’s Risk of Bias Tool for Randomized Trial (RoB 2) or the Joanna Brigg’s Institute (JBI)
Checklist for Critical Apprisal in RCTs and Clinical Trials, clear and guided procedures have
been developed in order to ensure the methodological quality of these various studies. However,
it is evident that these checklists and toolkits fail to include metrics that require these clinical
trials and RCTs to include diverse sampling procedures in their methodology. The United States
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is a nation full of rich racial and ethnic diversity. Over the years, the racial representation of the
U.S. has taken a shift, with people of color slowly surpassing white individuals as the emerging
majority population group. With knowledge of our nation’s deeply rooted history of oppression
perpetuated against minority people of color, it is clear that these facets of structural inequities
and racism have played a pervasive role in generating social disadvantage and health disparities
among people of color. As such, it is clear that the future directions of academic studies and
clinical trials must take into account the racial and ethnic diversity of the U.S. population in
order to determine whether these populations are disproportionately affected by certain disease
outcomes.
By failing to include racial and ethnic representation in clinical trial studies, there continues to be
a significant gap in our understanding of the various factors that may contribute to inequitable
and disproportionate burdens of health among minority populations. It is clear that the eight
studies included in this meta research project, as well as all other studies could be strengthened
by robust metrics that ensure diverse representation, such as the inclusion of an axis of diversity
sampling matrix by which demographic characteristics can be operationalized. Additionally,
organizations or programs that involve the critical review or appraisal of academic studies and
clinical trials must incorporate diverse frameworks and checklists to ensure sound representation
across various population demographic factors. By re-prioritizing the way we approach the
methodology and recruitment strategies of clinical trials, we can help to make promising strides
in our path towards population health equity in healthcare and medicine.
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APPENDICES
Appendix A: Search Strategy for Ovid MEDLINE:
Ovid MEDLINE(R) Search Strategy
Keyword Search

Number of
Studies Yielded

1 exp Polycystic Ovary Syndrome/

16526

2 Polycystic Ovary Syndrome.tw.

14536

3 Polycystic Ovar$.tw.

19195

4 PCOS.tw.

13347

5 PCOD.tw.

305

6 Stein-Leventhal Syndrome.tw.

566

7 Clomiphene.tw.

5258

8 exp Clomiphene/

5389

9 Letrozole.tw.

3333

10 exp Letrozole/

2326

11 Metformin.tw.

24358

12 exp Metformin/

16221

13 Gonadotropins.tw.

11282

14 exp Gonadotropins/

128948

15 exp Ovulation Induction/

14314

16 exp Ovulation/

26452

17 exp Fertility/

44401

18 exp Infertility/

70960

19 Randomized Controlled Trial.pt.
20 Controlled Clinical Trial.pt.

565060
94818

21 Randomized.ab.

557686

22 Randomised.ab.

110840

23 Clinical Trials as topic.sh.

199700

24 exp Animals/ not humans.sh.

4993841

((1 or 2 or 3 or 4 or 5 or 6) and (7 or 8 or 9 or 10 or 11 or 12 or 13 or
25 14) and (15 or 16 or 17 or 18) and (19 or 20 or 21 or 22 or 23)) not 24

541

limit 25 to (english language and yr=”1999 - 2021” and (clinical study
or clinical trial, all or clinical trial or controlled clinical trial or
26 randomized controlled trial))

303
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Appendix B: Search Strategy for PubMed:
PubMed Search Strategy
Keyword Search

Number of Studies
Yielded

1 “Polycystic Ovary Syndrome” [MeSH Terms]

16526

2 “Polycystic Ovary Syndrome [Title/Abstract]

14783

3 Polycystic Ovar* [Title/Abstract]

19387

4 "PCOS" [Title/Abstract]

13539

5 "PCOD" [Title/Abstract]

320

6 "Stein-Leventhal Syndrome" [Title/Abstract]

750

7 "Clomiphene" [Title/Abstract]

5329

8 Clomiphene [MeSH Terms]

5389

9 "Letrozole" [Title/Abstract]

3385

10 Letrozole [MeSH Terms]

2327

11 "Metformin" [Title/Abstract]

24761

12 Metformin [MeSH Terms]

16224

13 "Gonadotropins" [Title/Abstract]

15533

14 Gonadotropins [MeSH Terms]

128949

15 Ovulation Induction [MeSH Terms]

14313

16 Ovulation [MeSH Terms]

26450

17 Fertility [MeSH Terms]

44397

18 Infertility [MeSH Terms]

70960

19 (Animals [MeSH Terms]) NOT (Humans [MeSH Terms])

4993555

((#1 OR #2 OR #3 OR #4 OR #5 OR #6) AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR
20 #13 OR #14) AND (#15 OR #16 OR #17 OR #18) NOT (#19))

2144

((#1 OR #2 OR #3 OR #4 OR #5 OR #6) AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR
#13 OR #14) AND (#15 OR #16 OR #17 OR #18) NOT (#19)) Filters: Clinical Trial,
21 Randomized Controlled Trial, from 1999 - 2021

386

Final Search Strategy: ((("Polycystic Ovary Syndrome"[MeSH Terms] OR "Polycystic Ovary Syndrome"[Title/Abstract]
OR "polycystic ovar*"[Title/Abstract] OR "PCOS"[Title/Abstract] OR "PCOD"[Title/Abstract] OR "Stein-Leventhal
Syndrome"[Title/Abstract]) AND ("Clomiphene"[Title/Abstract] OR "Clomiphene"[MeSH Terms] OR
"Letrozole"[Title/Abstract] OR "Letrozole"[MeSH Terms] OR "Metformin"[Title/Abstract] OR "Metformin"[MeSH
Terms] OR "Gonadotropins"[Title/Abstract] OR "Gonadotropins"[MeSH Terms]) AND ("ovulation induction"[MeSH
Terms] OR "ovulation"[MeSH Terms] OR "fertility"[MeSH Terms] OR "infertility"[MeSH Terms])) NOT
("animals"[MeSH Terms] NOT "humans"[MeSH Terms])) AND ((clinicaltrial[Filter] OR randomizedcontrolledtrial[Filter])
AND (1999:2021[pdat]))
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Appendix C: Search Strategy for Scopus:
Scopus Search Strategy
Keyword Search

Search Within

Number of Studies
Yielded

1 {Polycystic Ovary Syndrome}

Title/Abstract/Keyword

22008

2 "Polycystic Ovar*"

Title/Abstract/Keyword

25793

3 {PCOS}

Title/Abstract/Keyword

16309

4 {PCOD}

Title/Abstract/Keyword

458

5 "Stein Leventhal"

Title/Abstract/Keyword

1140

6 #1 OR #2 OR #3 OR #4 OR #5

27308

7 Clomiphene

Title/Abstract/Keyword

8037

8 Clomifene

Title/Abstract/Keyword

12540

9 Letrozole

Title/Abstract/Keyword

11639

10 Metformin

Title/Abstract/Keyword

65473

11 Gonadotropin*

Title/Abstract/Keyword

129969

12 #7 OR #8 OR #9 OR #10 OR #11

210390

13 {Ovulation Induction}

All Fields

30569

14 Ovulation

All Fields

144907

15 Fertility

All Fields

980361

16 Infertility

All Fields

270945

17 13 OR #14 OR #15 OR #16

11391716

18 Randomi?ed Control* Trial

Title/Abstract/Keyword

959708

19 {RCT}

Title/Abstract/Keyword

35831

20 Randomi?ed

Title/Abstract/Keyword

1219516

21 Clinical Trial*

Title/Abstract/Keyword

2012380

22 Controlled Clinical Trial*

Title/Abstract/Keyword

1138787

23 #18 OR #19 OR #20 OR #21 OR #22

2422607

24 #6 AND #12 AND #17 AND #23

2180

25 Filter by Date: 1999 - 2021

1980

26 Limit to English

1876

27 Limit to Final Publication Stage

1866

FINAL SEARCH STRATEGY: ( ( TITLE-ABS-KEY ( {polycystic ovary syndrome} ) ) OR ( TITLE-ABS-KEY
( "polycystic ovar*" ) ) OR ( TITLE-ABS-KEY ( {pcos} ) ) OR ( TITLE-ABS-KEY ( {pcod} ) ) OR (
TITLE-ABS-KEY ( "stein leventhal" ) ) ) AND ( ( TITLE-ABS-KEY ( clomiphene ) ) OR ( TITLE-ABS-KEY (
clomifene ) ) OR ( TITLE-ABS-KEY ( letrozole ) ) OR ( TITLE-ABS-KEY ( metformin ) ) OR (
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TITLE-ABS-KEY ( gonadotropin* ) ) ) AND ( ( ALL ( {ovulation induction} ) ) OR ( ALL ( ovulation ) ) OR (
ALL ( fertility ) ) OR ( ALL ( infertility ) ) ) AND ( ( TITLE-ABS-KEY ( randomi?ed AND control* AND trial )
) OR ( TITLE-ABS-KEY ( {rct} ) ) OR ( TITLE-ABS-KEY ( randomi?ed ) ) OR ( TITLE-ABS-KEY ( clinical
AND trial* ) ) OR ( TITLE-ABS-KEY ( controlled AND clinical AND trial* ) ) ) AND ( LIMIT-TO (
PUBSTAGE , "final" ) ) AND ( LIMIT-TO ( PUBYEAR , 2021 ) OR LIMIT-TO ( PUBYEAR , 2020 ) OR
LIMIT-TO ( PUBYEAR , 2019 ) OR LIMIT-TO ( PUBYEAR , 2018 ) OR LIMIT-TO ( PUBYEAR , 2017 ) OR
LIMIT-TO ( PUBYEAR , 2016 ) OR LIMIT-TO ( PUBYEAR , 2015 ) OR LIMIT-TO ( PUBYEAR , 2014 ) OR
LIMIT-TO ( PUBYEAR , 2013 ) OR LIMIT-TO ( PUBYEAR , 2012 ) OR LIMIT-TO ( PUBYEAR , 2011 ) OR
LIMIT-TO ( PUBYEAR , 2010 ) OR LIMIT-TO ( PUBYEAR , 2009 ) OR LIMIT-TO ( PUBYEAR , 2008 ) OR
LIMIT-TO ( PUBYEAR , 2007 ) OR LIMIT-TO ( PUBYEAR , 2006 ) OR LIMIT-TO ( PUBYEAR , 2005 ) OR
LIMIT-TO ( PUBYEAR , 2004 ) OR LIMIT-TO ( PUBYEAR , 2003 ) OR LIMIT-TO ( PUBYEAR , 2002 ) OR
LIMIT-TO ( PUBYEAR , 2001 ) OR LIMIT-TO ( PUBYEAR , 2000 ) OR LIMIT-TO ( PUBYEAR , 1999 ) )
AND ( LIMIT-TO ( LANGUAGE , "english" ) )
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Appendix D: Search Strategy for Ovid Embase:
Ovid Embase Search Strategy
Keyword Search

Number of
Studies Yielded

1 exp ovary polycystic disease/

31479

2 exp ovary cyst/

44127

3 Polycystic Ovary Syndrome.tw.

19984

4 Polycystic Ovar$.tw.

26886

5 PCOS.tw.

20167

6 PCOD.tw.

442

7 Stein-Leventhal Syndrome.tw.

230

8 Clomiphene.tw.

6672

9 exp Clomifene/

6341

10 Letrozole.tw.

6355

11 Metformin.tw.

41399

12 Gonadotropin*.tw.

60097

13 exp Gonadotropin/

27748

14 exp Superovulation/

3179

15 exp Ovulation Induction/

17085

16 exp Hormonal Therapy/

303910

17 exp Ovulation/
18 Fertility.tw.
19 Infertility.tw.
20 "Clinical Trial*".tw.
21 exp Clinical Trial/

25947
109319
82880
619296
1689749

22 Randomi?ed Controlled Trial$.tw.

283084

23 exp Randomized Controlled Trial/

706430

24 Rct.tw.

46392

25 Randomized.tw.

870359

26 Randomised.tw.

174360

((1 or 2 or 3 or 4 or 5 or 6 or 7) and (8 or 9 or 10 or 11 or 12 or 13) and (14 or 15
27 or 16 or 17 or 18 or 19) and (20 or 21 or 22 or 23 or 24 or 25 or 26))

1529

limit 27 to (ovid full text available and full text and human and english language
28 and "remove preprint records" and yr="1999 - 2021")
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Appendix E: Search Strategy for Web of Science:
Web of Science Search Strategy
Keyword Search

Search Within

Number of Studies
Yielded

1 Polycystic Ovary Syndrome

Topic

20946

2 "Polycystic Ovar*"

Topic

24918

3 PCOS

Topic

14542

4 PCOD

Topic

257

5 Stein-Leventhal Syndrome

Topic

252

6 Clomiphene

Topic

5447

7 Letrozole

Topic

5903

8 Metformin

Topic

36664

9 Gonadotropins

Topic

11884

10 Ovulation Induction

All Fields

8776

11 Ovulation

All Fields

37994

12 Fertility

All Fields

228136

13 Infertility

All Fields

70209

14 Randomi?ed Control* Trial

Topic

474045

15 RCT

Topic

30243

16 Randomized

Topic

968036

17 Randomised

Topic

963698

18 Clinical Trial*

Topic

760585

19 Controlled Clinical Trial*

Topic

303704

((#1 OR #2 OR #3 OR #4 OR #5) AND (#6
OR #7 OR #8 OR #9) AND (#10 OR #11
OR #12 OR #13) AND (#14 OR #15 OR
20 #16 OR #17 OR #18 OR #19))

767

Refine by Publication Years: 1999-2021,
21 Open Access only, English Language

281
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